Incretin Mimetics for Patients Living with Type 2 Diabetes in a Predominantly Hispanic/Latino Population: Analysis of Prescribing Frequency and Predictors of Use

Clicks: 14
ID: 331484
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #211 of 247 articles by views in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 247 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Purpose Studies indicate incretin mimetic utilization is relatively low, especially among patients of Hispanic/Latino ethnicity. The objective of this study was to evaluate the frequency of incretin mimetic prescribing and identify predictors of prescribing within a predominantly Hispanic/Latino population at a county-funded hospital system. Methods A retrospective chart review of patients living with type 2 diabetes was conducted. The primary endpoint evaluated percentage of patients prescribed an incretin mimetic during August 2023 to August 2024. The secondary endpoint evaluated predictors to prescribing such as prescriber specialty, visit(s) with an ambulatory care clinical pharmacist, insurance status, clinical laboratory values, comorbidities, and medications used for concomitant comorbidities. Results A total of 502 patients were randomly selected for review, of which 42.6% (n = 214) were prescribed an incretin mimetic. Key predictors of prescribing were: sex (OR = 0.62, 95% CI [0.41, 0.92], P = 0.019), obesity (OR = 2.65, 95% CI [1.84, 3.82], P < 0.001), hyperlipidemia (OR = 1.57, 95% CI [1.04, 2.38], P = 0.032), endocrinology clinic visit(s), (OR = 3.91, 95% CI [2.43, 6.27], P < 0.001), and visit(s) with an ambulatory care clinical pharmacist (OR = 1.72, 95% CI [1.06, 2.81], P = 0.030). There was no significant difference in prescribing for Hispanic/Latino vs non-Hispanic/Latino populations within this study. Conclusion Incretin mimetics are historically underutilized among patients of Hispanic/Latino ethnicity despite their evidence-based benefits in patients with type 2 diabetes. Engagement with endocrinology and ambulatory care clinical pharmacy services may contribute to increased prescribing within clinical settings.
Reference Key
openalex_W7220715269 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cristian R Villalva, Kelli Sims, Olivia L. Ramey, Sarah Bermudez
Are you one of these authors? Claim your profile
Journal American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Year 2026
DOI
10.1093/ajhp/zxag321
URL
https://doi.org/10.1093/ajhp/zxag321
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.